Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telmisartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 6/20 | 1.00 |
| ▸ | PPARG | P37231 | 4/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ACE | P12821 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telmisartan SCHEMBL29356790 | 1.00 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29414101 | 1.00 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29691699 | 1.00 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL2122886 | 1.00 | AGTR1 (1.00) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL1071821 | 0.99 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL3384004 | 0.99 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL998659 | 0.99 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29032036 | 0.99 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL972356 | 0.99 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 | |
| Telmisartan SCHEMBL29113697 | 0.99 | AGTR1 (0.98) | AGTR1PPARGAGTR2KDM4EABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 32421 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075488-A | Compound preparation for treating hypertension and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122036956-A | Monoclonal antibody, nucleic acid molecule, detection kit and application of non-biphenyl tetrazolium sartan drugs | 中南大学湘雅三医院 | 2026-05-15 | — | — | CN | claimed |
| CN-122036573-A | Drug design strategy for releasing hydrogen sulfide based on enzymolysis thiocarbonyl and application of drug design strategy in diclofenac-like drug modification | 中国药科大学 | 2026-05-15 | — | — | CN | claimed |
| CN-122028915-A | Frontotemporal lobar degenerative disease therapeutic agent and therapeutic composition | 凯制药股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260124187-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | THE GEORGE INST FOR GLOBAL HEALTH (AU) | 2026-05-07 | — | — | US | claimed |
| US-20260124180-A1 | METHOD OF TREATING AFFECTIVE DISORDERS AND PERSONALITY DISORDERS | HB BIOTECH, INC. (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| EP-0831911-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0759754-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DePadova, Anthony S. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1997002032-A1 | METHOD OF TREATING RENAL DISEASE USING AN ACE INHIBITOR AND AN AII ANTAGONIST | MERCK & CO., INC. (US) | 1997-01-23 | — | — | WO | claimed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | claimed |
| WO-1996040255-A2 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION THERAPY OF AN ANGIOTENSIN II ANTAGONIST AND AN EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040257-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040258-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040256-A1 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION OF AN ANGIOTENSIN II ANTAGONIST AND SPIRONOLACTONE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1995029674-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 1995-11-09 | — | — | WO | claimed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | claimed |